A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease

被引:11
|
作者
Ettcheto, Miren [1 ,2 ,3 ,4 ]
Busquets, Oriol [1 ,2 ,3 ,4 ]
Espinosa-Jimenez, Triana [1 ,3 ,4 ]
Verdaguer, Ester [3 ,4 ,5 ]
Auladell, Carme [3 ,4 ,5 ]
Camins, Antoni [1 ,3 ,4 ]
机构
[1] Univ Barcelona, Fac Pharm & Food Sci, Dept Pharmacol Toxicol & Therapeut Chem, Av Joan XXIII 27-31, E-08028 Barcelona, Spain
[2] Univ Rovira & Virgili, Fac Med & Life Sci, Dept Biochem & Biotechnol, Reus, Spain
[3] Carlos III Hlth Inst, Biomed Res Networking Ctr Neurodegenerat Dis CIBE, Madrid, Spain
[4] Univ Barcelona, Inst Neurosci, Barcelona, Spain
[5] Univ Barcelona, Dept Cellular Biol Physiol & Immunol, Barcelona, Spain
关键词
Neurodegeneration; Alzheimer's disease; Parkinson's disease; oxidative stress; neuroinflammation; ER stress; glutamate; calcium; BLOOD-BRAIN-BARRIER; AGGREGATION INHIBITOR THERAPY; A-BETA; INSULIN-RESISTANCE; AMYLOID HYPOTHESIS; COGNITIVE DECLINE; BACE1; INHIBITOR; P-GLYCOPROTEIN; DOUBLE-BLIND; CLINICAL DEVELOPMENT;
D O I
10.2174/1381612826666200211121416
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Late-onset Alzheimers disease (LOAD) is a neurodegenerative disorder that has become a worldwide health problem. This pathology has been classically characterized for its affectation on cognitive function and the presence of depositions of extracellular amyloid beta-protein (A beta) and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau protein. To this day, no effective treatment has been developed. Multiple strategies have been proposed over the years with the aim of finding new therapeutic approaches, such as the sequestration of A beta in plasma or the administration of anti-inflammatory drugs. Also, given the significant role of the insulin receptor in the brain in the proper maintenance of cognitive function, drugs focused on the amelioration of insulin resistance have been proposed as potentially useful and effective in the treatment of AD. In the present review, taking into account the molecular complexity of the disease, it has been proposed that the most appropriate therapeutic strategy is a combinatory treatment of several drugs that will regulate a wide spectrum of the described altered pathological pathways.
引用
收藏
页码:1286 / 1299
页数:14
相关论文
共 50 条
  • [1] Disease-Modifying Alzheimer's Disease Therapeutic Candidate
    Kelleher-Andersson, Judith
    NEUROTHERAPEUTICS, 2012, 9 (03) : 679 - 680
  • [2] Disease-modifying Therapeutic Approaches for Alzheimer's Disease (2021)
    Froelich, Lutz
    Hausner, Lucrezia
    NERVENARZT, 2022,
  • [3] Disease-modifying targets and strategies for Alzheimer's disease and Parkinson's disease
    Gao, Xiaoya
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [4] Therapeutic news in Alzheimer?s disease: Soon a disease-modifying therapy?
    Villain, N.
    REVUE NEUROLOGIQUE, 2022, 178 (05) : 437 - 440
  • [5] Therapeutic news in Alzheimer's disease: soon a disease-modifying therapy?
    Villain, Nicolas
    GERIATRIE ET PSYCHOLOGIE NEUROPSYCHIATRIE DE VIEILLISSEMENT, 2022, 20 (02): : 256 - 260
  • [6] Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease
    Ettcheto, Miren
    Busquets, Oriol
    Camins, Antoni
    NEURAL REGENERATION RESEARCH, 2019, 14 (10) : 1721 - 1725
  • [7] Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease
    Miren Ettcheto
    Oriol Busquets
    Antoni Camins
    Neural Regeneration Research, 2019, 14 (10) : 1721 - 1725
  • [8] Overview of potential targets for disease-modifying drugs in Alzheimer's disease
    Cuello, A. Claudio
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 4 - 4
  • [9] Neuroinflammation in Alzheimer's disease:: Potential targets for, disease-modifying drugs
    Hüll, M
    Hampel, H
    NEUROINFLAMMATION - FROM BENCH TO BEDSIDE, 2002, 39 : 159 - 178
  • [10] Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease
    Beher, D
    Graham, SL
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) : 1385 - 1409